Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen

Autor: João Bernardes, Rufino Silva, João Pedro Marques, Joaquim Murta, Joana Providência, Tiago Rodrigues, Mariana A Oliveira
Rok vydání: 2018
Předmět:
Male
medicine.medical_specialty
Visual acuity
Article Subject
genetic structures
Recombinant Fusion Proteins
Visual Acuity
lcsh:Medicine
Angiogenesis Inhibitors
Loading dose
General Biochemistry
Genetics and Molecular Biology
Macular Degeneration
03 medical and health sciences
0302 clinical medicine
Ranibizumab
Ophthalmology
Humans
Medicine
030212 general & internal medicine
Aged
Retrospective Studies
Aflibercept
Aged
80 and over
General Immunology and Microbiology
business.industry
Incidence (epidemiology)
lcsh:R
Retrospective cohort study
General Medicine
Macular degeneration
medicine.disease
Regimen
Receptors
Vascular Endothelial Growth Factor
Treatment Outcome
Intravitreal Injections
030221 ophthalmology & optometry
Female
medicine.symptom
business
Tomography
Optical Coherence
Research Article
Follow-Up Studies
medicine.drug
Zdroj: BioMed Research International, Vol 2018 (2018)
BioMed Research International
ISSN: 2314-6141
2314-6133
DOI: 10.1155/2018/9276580
Popis: Intravitreal injections of antivascular endothelial growth factors have been considered a milestone in the treatment of neovascular age-related macular degeneration (nAMD). However, the increasing incidence of AMD and the burden of visits and injections overcharge both the patient and the healthcare systems. Real-world solutions depend on treatment protocols aimed at optimizing the number of clinical visits while guaranteeing good functional outcomes. We performed a retrospective analysis of 72 eyes from 63 naïve patients diagnosed with nAMD that underwent a fixed intravitreal protocol consisting of bimonthly injections after a three-month loading dose, with either Aflibercept or Ranibizumab (no predefined criteria for treatment selection). Best corrected visual acuity (BCVA) and optical coherence tomography were analyzed at baseline and during follow-up clinical visits (months 3, 6, 12, and 18). From the included participants, 42 followed a fixed regimen with Aflibercept and 30 with Ranibizumab. At the 12-month visit, there was not a statistically significant difference in the mean change of BCVA between the two groups (p=0.121); however, the mean difference in the central retinal thickness was significantly superior in the Aflibercept group (-142.2 versus -51.5, p=0.011). The described fixed regimen seems to be efficient in the treatment of nAMD in a clinical practice setting.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje